Key Insights

Highlights

Treatment Research

6 treatments under study, led by Iparomlimab And Tuvonralimab Injection

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07887971Phase 1Recruiting

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

NCT07349225Phase 2Not Yet RecruitingPrimary

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Iparomlimab And Tuvonralimab Injection1
  • Targeted Radiation Therapy1
  • 225acacaky2519 Therapeutic1
  • 64cucuaky2519 Imaging1
  • Cisplatin1

Active Sponsors

  • Aktis Oncology, Inc.1
  • The Second Affiliated Hospital of Dalian Medical University1

Related Conditions

  • Hnscc1
  • Head Neck Cancer Squamous Cell Metastatic1
  • Crc1
  • Small Cell Lung Cancer Extensive Stage1
  • Crc Colorectal Cancer1

Activity Timeline